ArticleThe Journal of infectious diseases2018
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.
Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04319367 (A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies), which is not on this map. Cited by 147 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs) vs ART Plus Placebo in Treated Primary or Early Stage HIV Infection on Viral Control Off ART
Who cites it
147 citing papers in PubMed, 1 synthesis or guideline pooled it, 196 citations in OpenAlex.
- Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies.Nature communications · 2025Pooled it
- Trial
- Virological and Immunological Outcomes of Combined Therapeutic Interventions and Dendritic Cell Therapy in People With HIV.The Journal of infectious diseases · 2025Trial
- Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study.Nature medicine · 2025Trial
- Long-term effect of temporary ART initiated during primary HIV-1 infection on viral persistence.Nature communications · 2025Trial
- Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood.The Journal of infectious diseases · 2025Trial
- Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.AIDS research and human retroviruses · 2022Trial
- Trial
- Predictors of Cell-Associated Human Immunodeficiency Virus (HIV)-1 DNA Over 1 Year in Very Early Treated Infants.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.The Lancet. Microbe · 2022Trial
- CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.The Journal of clinical investigation · 2021Trial
- Kinetics of Plasma HIV Rebound in the Era of Modern Antiretroviral Therapy.The Journal of infectious diseases · 2020Trial
- Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection.Science translational medicine · 2019Trial
- Constitutive natural killer cell features associated with post-treatment control of SIV infection in the pVISCONTI study.Nature communications · 2026Article
- Unique CD8bioRxiv : the preprint server for biology · 2026Article
- CD8ɑ+ cells suppress SIV replication without the development of mutations within MHC class-I-restricted epitopes during post-treatment control.Journal of virology · 2026Article
- Early intervention, lasting impact: benefits of early antiretroviral therapy and implications for posttreatment control.Current opinion in HIV and AIDS · 2026Review
- Opportunities and challenges in achieving a functional cure for HIV.Infectious diseases & immunity · 2026Review
- Impact of sex differences in adult and paediatric HIV-1 cure.Current opinion in HIV and AIDS · 2026Review
87 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 18 institutions in 2 countries.
Funding
Abstract
Background: HIV posttreatment controllers are rare individuals who start antiretroviral therapy (ART), but maintain HIV suppression after treatment interruption. The frequency of posttreatment control and posttreatment interruption viral dynamics have not been well characterized. Methods: Posttreatment controllers were identified from 14 studies and defined as individuals who underwent treatment interruption with viral loads ≤400 copies/mL at two-thirds or more of time points for ≥24 weeks. Viral load and CD4+ cell dynamics were compared between posttreatment controllers and noncontrollers. Results: Of the 67 posttreatment controllers identified, 38 initiated ART during early HIV infection. Posttreatment controllers were more frequently identified in those treated during early versus chronic infection (13% vs 4%, P < .001). In posttreatment controllers with weekly viral load monitoring, 45% had a peak posttreatment interruption viral load of ≥1000 copies/mL and 33% had a peak viral load ≥10000 copies/mL. Of posttreatment controllers, 55% maintained HIV control for 2 years, with approximately 20% maintaining control for ≥5 years. Conclusions: Posttreatment control was more commonly identified amongst early treated individuals, frequently characterized by early transient viral rebound and heterogeneous durability of HIV remission. These results may provide mechanistic insights and have implications for the design of trials aimed at achieving HIV remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.